Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
Cardiology and Therapy
doi 10.1007/s40119-020-00165-8
Full Text
Open PDFAbstract
Available in full text
Date
March 9, 2020
Authors
Publisher
Springer Science and Business Media LLC